Sotera Health Posts Solid Q3, Reaffirms 2026 Outlook as Leverage Falls to 2.9x
SHC sits 36% above its 52-week low of $13.09.
Summary
Sotera Health delivered Q3 revenue of $324.9 million, up from $311.3 million a year ago, with net income of $58.4 million and diluted EPS of $0.20 versus $0.17. Adjusted EBITDA margin rose nearly 100 basis points sequentially to 52.5%, and Sterigenics and Nelson Labs grew constant-currency revenue 8.2% and 9.2% respectively. Nordion revenue fell 11.5% in constant currency on expected Cobalt-60 harvest timing, a known swing factor rather than a demand problem. The balance sheet is the quieter story: net leverage improved to 2.9x from 3.2x at year-end 2025, inside the 2.0x-3.0x target, and Moody's upgraded the credit rating in early October. Management reaffirmed full-year guidance of $1.233-$1.250 billion in revenue and $632-$641 million in Adjusted EBITDA, though it trimmed the expected FX tailwind to 70 basis points from 100. This follows the strong Q2 print in August that also came with raised guidance; the reaffirmation here suggests the bar is now holding rather than rising. Earnings call is at 9:00 a.m. ET today.
At the time of this announcement, SHC was trading at $17.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $13.09 to $19.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.